Short-term real-world experience with baricitinib treatment in Danish adults with moderate-severe atopic dermatitis

被引:11
作者
Vittrup, Ida [1 ,2 ]
Elberling, Jesper [2 ]
Skov, Lone [2 ]
Ibler, Kristina Sophie [3 ]
Jemec, Gregor B. E. [3 ]
Mortz, Charlotte G. [4 ,5 ]
Bach, Rasmus Overgaard [4 ,5 ]
Bindslev-Jensen, Carsten [4 ,5 ]
Dalager, Maiken Glud [6 ]
Egeberg, Alexander [1 ]
Kamstrup, Maria [1 ]
Deleuran, Mette [7 ]
Vestergaard, Christian [7 ]
Thyssen, Jacob P. [1 ,8 ]
机构
[1] Copenhagen Univ Hosp Bispebjerg & Frederiksberg, Dept Dermatol, Copenhagen, Denmark
[2] Copenhagen Univ Hosp Herlev & Gentofte, Dept Dermatol & Allergy, Copenhagen, Denmark
[3] Univ Copenhagen, Zealand Univ Hosp, Dept Dermatol, Roskilde, Denmark
[4] Odense Univ Hosp, Dept Dermatol, Odense, Denmark
[5] Odense Univ Hosp, Allergy Ctr, Odense, Denmark
[6] Aalborg Univ Hosp, Dept Dermatol, Aalborg, Denmark
[7] Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark
[8] Copenhagen Univ Hosp Bispebjerg & Frederiksberg, Dept Dermatol & Venereol, Copenhagen, Denmark
关键词
D O I
10.1111/jdv.18804
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
引用
收藏
页码:E543 / E546
页数:4
相关论文
共 6 条
  • [1] Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): A Danish Real-world Evidence Atopic Dermatitis Treatment Registry
    Larsen, Henrik H. P.
    Vittrup, Ida
    Ruge, Iben F.
    Elberling, Jesper
    Skov, Lone
    Ibler, Kristina
    Jemec, Gregor B. E.
    Mortz, Charlotte G.
    Bach, Rasmus O.
    Bindslev-Jensen, Carsten
    Dalager, Maiken
    Agner, Tove
    Deleuran, Mette
    Vestergaard, Christian
    Thyssen, Jacob P.
    [J]. ACTA DERMATO-VENEREOLOGICA, 2022, 102
  • [2] Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis A Randomized Clinical Trial
    Reich, Kristian
    Kabashima, Kenji
    Peris, Ketty
    Silverberg, Jonathan, I
    Eichenfield, Lawrence F.
    Bieber, Thomas
    Kaszuba, Aleksandra
    Kolodsick, Jill
    Yang, Fan E.
    Gamalo, Margaret
    Brinker, Dennis R.
    Delozier, Amy M.
    Janes, Jonathan M.
    Nunes, Fabio P.
    Thyssen, Jacob P.
    Simpson, Eric L.
    [J]. JAMA DERMATOLOGY, 2020, 156 (12) : 1333 - 1343
  • [3] Rogner D, 2022, ACTA DERM-VENEREOL, V102, P1
  • [4] Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials
    Simpson, E. L.
    Lacour, J. -P.
    Spelman, L.
    Galimberti, R.
    Eichenfield, L. F.
    Bissonnette, R.
    King, B. A.
    Thyssen, J. P.
    Silverberg, J. I.
    Bieber, T.
    Kabashima, K.
    Tsunemi, Y.
    Costanzo, A.
    Guttman-Yassky, E.
    Beck, L. A.
    Janes, J. M.
    DeLozier, A. M.
    Gamalo, M.
    Brinker, D. R.
    Cardillo, T.
    Nunes, F. P.
    Paller, A. S.
    Wollenberg, A.
    Reich, K.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (02) : 242 - 255
  • [5] Real-world effectiveness and safety of baricitinib in Japanese patients with atopic dermatitis: A single-center retrospective study
    Uchiyama, Akihiko
    Fujiwara, Chisako
    Inoue, Yuta
    Motegi, Sei-ichiro
    [J]. JOURNAL OF DERMATOLOGY, 2022, 49 (04) : 469 - 471
  • [6] Vittrup I, 2022, J EUR ACAD DERMATOL